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BACKGROUND: The BRCA2 gene is responsible for a high number of hereditary breast and ovarian cancers, and studies of the BRCA2
biological functions are limited by the lack of models that resemble the patient’s tumour features. The aim of this study was to
establish and characterise a new human breast carcinoma xenograft obtained from a woman carrying a germline BRCA2 mutation.
METHODS: A transplantable xenograft was obtained by grafting a breast cancer sample into nude mice. The biological and genetic
profiles of the xenograft were compared with that of the patient’s tumour using histology, immunohistochemistry (IHC), BRCA2
sequencing, comparative genomic hybridisation (CGH), and qRT–PCR. Tumour response to standard chemotherapies was
evaluated.
RESULTS: Histological profile identified the tumour as a basal-like triple-negative breast cancer. Targeted BRCA2 DNA sequencing of
the xenograft showed the presence of the mutation previously identified in the carrier. Comparative genomic hybridisation array
profiles of the primary tumour and the xenograft revealed a high number of similar genetic alterations. The therapeutic assessment
of the xenograft showed sensitivity to anthracyclin-based chemotherapy and resistance to docetaxel. The xenograft was also highly
sensitive to radiotherapy and cisplatin-based treatments.
CONCLUSIONS: This study describes a new human breast cancer xenograft obtained from a BRCA2-mutated patient. This xenograft
provides a new model for the pre-clinical drug development and for the exploration of the drug response biological basis.
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Germline BRCA2 mutations in female carriers confer a cumulative
breast cancer risk at age 70 years of 49% (95% CI: 40–57%),
an ovarian cancer risk of 18% (95% CI: 13–23%), and a moderate
increased risk of pancreatic cancer (Chen and Parmigiani, 2007).
Although the available evidence is not sufficient to decisively
conclude that the clinical outcome of women with BRCA1/2-
associated breast cancer differs significantly from those of women
with sporadic tumours, BRCA1-associated breast cancer often
manifests adverse outcome features.
Establishment of pre-clinical models, which accurately reflect
the genetic and phenotypic features of primary tumours, and their
response to treatment, is an important step in identifying novel
therapeutic targets and testing new treatment modalities. New
strategies may take advantage of the specific DNA repair defects
inherent in BRCA-deficient cells, such as the defect in homologous
recombination. In fact, most of the insights into the functions of
the BRCA2 protein have included key insights from studies of mice
by the use of gene targeting and from studies of altered mouse
embryonic cells (Evers and Jonkers, 2006).
BRCA2 has a key role in DNA double-strand break repair and
cell-cycle control. BRCA2-related defects are associated with
chromosomal abnormalities, a hallmark of the genomic instability
that could foster tumourigenesis. Moreover, BRCA2 participates in
the regulation of mitosis and cytokinesis that contribute to
numerical chromosomal stability.
Although conventional, non-conditional, mouse mutants might
be used to model familial forms of cancer, they do not mimic
sporadic tumourigenesis because the initiating mutation is present
in all cells of the body, including those that constitute the tumour
microenvironment.
Moreover, embryonic lethality and development of non-
epithelial tumours are another important limitation of genetically
mutated Brca2 mice. Some murine Brca2 mutant mammary
tumour models develop mammary tumours with histopatho-
logical features that are significantly different to their human
counterparts. Although some studies report a strikingly similar
histopathology in BRCA1 null breast tumours from mice and
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shumans (Dennis, 1999; Xu et al, 1999), their relevance to the
human situation remains to be demonstrated. The most used
human BRCA2-mutated model is the CAPAN1 pancreatic cell line
that is mainly used to understand drug resistance in BRCA1/2
mutation carrier, as well as in defining functionally important
domains within BRCA2 (Edwards et al, 2008). To date, only one
BRCA2-mutated breast cancer xenografts (MX1) is available,
(Donawho et al, 2007) but its characterisation has not been
described in detail.
Genetic testing to identify BRCA1/2 mutations is widely available
and commonly employed. As a result, increasing numbers of
women are aware that they are mutation carriers at the time of
their cancer diagnosis. Unfortunately, current knowledge is not
sufficient to mandate specific local or systemic treatments that are
tailored to BRCA1/2 mutation carriers. In fact, the available studies
examining the issue of whether BRCA1/2-associated breast cancer
should be treated differently from sporadically occurring, non-
familial disease are almost exclusively retrospective and limited by
small size and various ascertainment biases.
Recently, inhibitors of the DNA repair proteins, poly
(ADP-ribose) polymerase 1 and 2 (PARP1/2), have been shown
to be selectively cytotoxic to tumour cells with BRCA1 or BRCA2
deficiency. Preclinical data, including that generated with a limited
array of tumour cell line xenografts, suggest that PARP inhibitors
can act as single agents to selectively kill cancers with BRCA1 or
BRCA2 mutations, and phase I clinical trial results confirm that
PARP inhibitors have some single-agent activity in cancers with
BRCA1/2 mutations (Fong et al, 2009). However, little is known
about the long-term effects of these drugs and it seems likely that
some tumours may have de novo resistance or acquired resistance
(Ashworth, 2008). Thus, definitive answers remain elusive, and
preclinical evaluation of new targeted therapy is limited by the lack
of suitable preclinical models (Robson, 2007a).
Here, we report the establishment and characterisation of a novel
xenograft, human breast cancer xenograft (HBCx-17) established
from a breast cancer in a woman carrying a BRCA2 germline
mutation. We show that this xenograft accurately reflects the genetic
and the phenotypic features of the primary tumour, thus providing a
new model to test new therapies for BRCA2-mutated patients.
MATERIALS AND METHODS
Animals and establishment of tumour xenografts
The breast cancer specimen was obtained with informed consent
from the patient undergoing surgery. Fresh tumour fragments
were grafted into the interscapular fat pad of 8–12-week-old
female Swiss nude mice, under avertin anaesthesia. Mice were
maintained in specific pathogen-free animal housing (Institut
Curie, Paris, France) and received oestrogen (8mgml
 1) diluted in
drinking water. Xenografts appeared at the graft site about 1
month after grafting. One xenograft was subsequently transplanted
from mouse to mouse and stocked frozen in DMSO-fetal calf
serum solution or frozen dried in nitrogen for further studies, and
a fragment was fixed in phosphate-buffered saline (PBS) 10%
formol for histological studies. The experimental protocol and
animal housing were in accordance with institutional guidelines
as put forth by the French Ethical Committee (Agreement B75-05–
18, France).
Histology and IHC
The morphology of patients’ tumour tissue and of the xenograft
was compared using paraffin-embedded sections and standard
protocols (Vincent-Salomon et al, 2007). Tumours were removed
from mice and immediately fixed in a 10% formol/PBS solution.
Determination of oestrogen receptor, progesterone receptor,
ERBB2, Ki67, cytokeratin (CK) 5/6, and epidermal growth factor
receptor (EGFR) status by IHC was done according to previously
published protocols (Vincent-Salomon et al, 2007).
To search for spontaneous lung metastasis of the HBCx-17
xenograft, mice were killed when the tumour reached an ethical
size (about 2500mm
3), and lungs were formalin-fixed in-toto for
histological evaluation.
Compounds and therapeutic assays
Doxorubicin, 2mgkg
 1 (Adriamycin, Teva Pharmaceuticals, Paris,
France), and cyclophosphamide, 100mgkg
 1 (Endoxan, Baxter,
Maurepas, France), diluted in 0.9% NaCl, and docetaxel, 20mgkg
 1
(Taxotere, Sanofi-Aventis, Paris, France), diluted in its specific
excipient, were given by intraperitoneal (i.p.) route at 3-week intervals.
Ifosfamide, 90mgkg
 1 (Holoxan, Baxter) was given by i.p. route on
three consecutive days every 3 weeks. Cisplatin, 1mgkg
 1 (Mylan,
Hoeilaart, Belgium) was diluted in 0.9% NaCl and given weekly by i.p.
route. Capecitabine (Xeloda, Roche, Basel, Switzerland), 540mg per kg
per day was diluted in glucose 5% and given per os in two
administrations a day. Radiotherapy was administered locally with
one dose of 8Gy or two weekly fraction doses of 8 and 7Gy,
respectively, for a total dose of 15Gy. Irradiation experiments were
done using a caesium source having a dose rate of 2.15Gy per min.
Therapeutic assessments were performed as described elsewhere
(Marangoni et al, 2007). Briefly, tumour volume was calculated as
V¼axb
2/2, a being the largest diameter and b the smallest.
Treatment was initiated when tumours in each group achieved
an average volume of B170–200mm
3. For each tumour, Vs were
reported to the initial volume as relative tumour volume (RTV).
Means (and s.e.) of RTV in the same treatment group were
calculated, and growth curves were established as a function of
time. Optimal tumour growth inhibition (TGI) of treated tumours
vs controls was calculated as the ratio of the mean RTV in treated
group to the mean RTV in the control group at the same time.
Statistical significance of TGI was calculated by the paired
Student’s t-test, by comparing the individual RTVs in the treated
and control groups. Mice were ethically killed when the tumour
volume reached about 2500mm
3.
DNA sequencing
Screening for BRCA2 point and small size mutations was performed
through analysis of genomic DNA from patient’s tumour. In all, 100ng
of DNA was amplified using Taq ABgene 0.025Uml
 1 (ABgene UK,
ref: http://www.abgene.com), 4 0.2mM dNTPs, 1.5mM MgCl2,a n d
0.3mM of each primer in a final reaction volume of 50ml. Amplification
was performed with an initial denaturation step at 941Cf o r5 m i n
followed by 35 PCR cycles: denaturation at 941C for 30s, annealing at
541C for 30s, and elongation at 721Cf o r3 0s .
PCR products were separated by agarose gel electrophoresis,
purified (Macherey Nagel, Du ¨ren, Germany), and sequenced using
one of the PCR primers (usually the forward primer, except in the
case of poor sequence quality). Big Dye Cycle Sequencing
Reactions and an ABI3130XL automated sequencer (Applied
Biosystems, Foster City, CA, USA). Seqscape (Applied Biosystems)
software was used for sequence analysis.
Genotypage
Allelic loss was analysed by amplification of two microsatellite
markers flanking the BRCA2 gene: D13S260 and D13S1701.
Germline DNA, obtained from a blood sample, and tumour and
xenograft DNA were compared. In all, 100ng of DNA was
amplified using AmpliTaq Gold 5Uml
 1 (Applied Biosystems),
4 0.2mM dNTPs, 1.5mM MgCl2, and 0.3mM of each primer in a
final reaction volume of 10ml. Amplification was performed with
an initial denaturation step at 941C for 5min followed by 30 PCR
cycles: denaturation at 941C for 30s, annealing at 551C for 30s, and
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selongation at 721C for 30s. A total of 1ml of PCR products was
mixed with 19ml of Formamide Hi-Di (Applied Biosystems) and
0.5ml of Genescan 400 ROX Size Standard (PE Applied Biosystems)
and separated on ABI3130XL automated sequencer (Applied
Biosystems). Genemapper (Applied Biosystems) software was used
for genotype analysis.
Quantitative multiplex PCR of short fluorescent fragments
Quantitative multiplex PCR of short fluorescent fragments is a
sensitive method for the detection of large gene deletions or
duplications. It is based on the simultaneous amplification of short
genomic fragments using dye-labelled primers under quantitative
conditions (Casilli et al, 2002; Tournier et al, 2004). PCR products
were analysed on a sequencing platform used in the fragment
analysis mode, where both peak heights and areas are proportional
to the quantity of template present for each target sequence. Nine
amplicons of BRCA2 between 180 and 300bp were amplified in the
same multiplex reaction. As an internal control, we included in
each reaction a fragment of different gene in which deletion was
not expected (MLH1 exon 14). One primer from each primer pair
was 50-labeled with 6-FAM fluorochrome.
In all, 100ng of two genomic DNA from the xenograft, two
normal control, and one BRCA2-mutated control were amplified in
a final volume of 25ml, including 0.06–0.24mmoll
 1 for each
primer and 12.5ml of QIAGEN master mix (QIAGEN multiplex
PCR Kit). After an initial denaturation step, samples underwent
23 cycles (30s at 951C, 40s at 541C, and 60s at 721C). After the
multiplex reactions, the DNA fragments were separated on an
ABI3130XL automated sequencer and analysed using Genemapper
Software (Applied Biosystems).
For this analysis, we used visual sample-to-control comparison.
We estimated allele dosage by superimposing the electrophero-
gram of the tested sample onto the corresponding image for a
control DNA sample, after adjusting the vertical scale of the
internal control amplicon. Allelic losses of one or more amplicons
are represented by a two-fold reduction in the intensity (peak
heights) of an amplicon of the sample analysed. Allelic duplication
of one or more amplicons is represented by a 0.5-fold rise in the
intensity (peak heights) of an amplicon of the sample analysed.
Protein analysis
Whole-cell protein extracts were prepared from tumour samples
by homogenising the tissue in RIPA buffer (10mM Tris-Cl, pH 7.5,
150mM NaCl, 1mM EDTA, 1% Nonidet P40, 0.5% sodium
deoxycholate, 0.1% SDS, protease inhibitors). Protein concentra-
tions were measured with Bio-Rad Protein Assay Reagent
(Bio-Rad, Marnes-la-Coquette, France). Immunoprecipitations
were performed by incubating Protein G beads (Sigma, Steinheim,
Germany), 1–2mg of precleared cell lysate, and anti-BRCA2
mouse monoclonal Ab-1 antibody (dilution 1:200; Merck) over-
night at 41C. Beads were subsequently washed three times in cold
lysis buffer, after which 2  loading buffer was added and the
samples were boiled for 2min before SDS–PAGE. For western
blotting analysis, lysates were subjected to electrophoresis on
Novex precast gels (Invitrogen, Cergy Pontoise, France) and
immunoblotted overnight at 41C with the following antibodies:
anti-BRCA2 and anti-b-tubulin, T4026 (Sigma). This was followed
by incubation with anti-IgG-horseradish peroxidase and enhanced
chemiluminescent detection (GE Healthcare Bio-Sciences AB,
Uppsala, Sweden). As a control, full-length BRCA2 was detected
in lysates generated from 293T cells.
Detection of ERa, Ki67, and ERBB2 by quantitative
RT–PCR
Total RNA extraction and cDNA synthesis were done as previously
described from 1mg total RNA (de Cremoux et al, 2004).
ERa, Ki67, and ERBB2 transcripts were quantified using real-time
quantitative reverse transcription–PCR (RT–PCR) assays. The
nucleotide and probe sequences, and the conditions of PCR have
been previously described (de Cremoux et al, 2007). Results were
expressed as N-fold differences in target gene expression relative to
a reference gene defined as ‘N target’.
Array-based CGH
A genome-wide resource of 5244 fluorescence in situ hybridisation
mapped, sequenced BAC and PAC clones, verified for gene and
marker content were represented as immobilised DNA targets on
glass slides for array-based CGH analysis, allowing a mean
resolution of 0.5Mb all along the genome. Each clone was spotted
in quadruplicate on a slide prepared by Integragen (Evry, France)
and developed by the Institut National de la Sante et de la
Recherche Medicale Unit U830. After extraction, 1.5mg of each test
and control DNA samples were digested with DpnII enzyme
(Ozyme, Saint-Quentin en Yveline, France) and purified with a
QIAquick PCR purification kit (Qiagen, Courtaboeuf, France). They
were then labelled by random priming using a Bioprime DNA
labelling kit (Invitrogen) with the appropriate cyanine dye (Cy3 or
Cy5; PerkinElmer, Waltham, MA, USA). The control and test DNA
were coprecipitated with Cot-1 DNA (Invitrogen), denatured, and
resuspended in hybridisation buffer (50% formamide). Competitive
cohybridisation was done on CGH array slides. After 24-h
hybridisation, slides were washed with SDS and saline citrate,
dried, and scanned using a 4000B scan (Axon, Orleans, CA, USA).
Image analysis was done with Genepix 5.1 software (Axon) and
processed using a software developed at the Curie Institute (La
Rosa et al, 2006). Any BAC with less than two replicates flagged for
not fulfilling qualitative spot criteria was excluded. A ratio o0.8
was considered as a loss, a ratio 41.2 was considered as a gain, and
a ratio 41.5 was considered as amplification (Auger et al, 2006).
Data analysis was based on the normalised ratios of Cy5/Cy3
signals observed for each BAC clone that previously passed the flag
assessment procedure. For autosomal chromosomes, the loss of a
given locus was defined by a ratio p0.8, a gain was defined by a
ratio X1.2 and o2.0, and an amplicon was defined by a ratio
X2.0. For X chromosomes, a loss was defined by a ratio p1.2, a
gain was defined by a ratio X1.7, and an amplicon was defined by
a ratio X2.5. The data analysis was done according to previously
published protocols (Vincent-Salomon et al, 2007).
Clinical features of the patient
The BRCA2 mutation carrier from whom the HBCx-17 xenograft
was obtained was a 37-year-old woman who was affected at 32 years
of age for a first invasive ductal carcinoma (IDC) of grade III that
was treated with surgery, FEC100, and radiotherapy. After 6 years,
she developed a contralateral IDC and was treated by upfront
surgery followed by six cycles of docetaxel and radiotherapy. The
xenograft was established from the second carcinoma. The patient
tumour was C-ERBB2, oestrogen-, and progesterone-receptor
negative, with a high mitotic index. The patient had a strong
familial history of breast and ovarian cancer. BRCA1/2 gene testing,
performed with the informed consent of the patient, identified a
mutation in the BRCA2 gene: c.6033_6034delTT; p.ser2012GlnfsX5.
RESULTS
Histology of xenograft and comparison with patient
tumour
Histopathological analysis was performed with the primary
tumour and the xenograft HBCx-17 at passage 6. As shown in
Figure 1A and B, the histology of the original tumour was
conserved in the xenograft. Indeed, HBCx-17 showed an infiltrating
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sductal carcinoma with typical loss of tubule formation, prominent
nuclear pleomorphism, and mitotic activity. Irregular infiltration
of stroma was observed in both patient and xenografts. Assessment
of tumour proliferation using Ki67 staining showed a high
proliferative rate in the primary tumour, which was increased in
the xenograft (Figure 1C and D). Both primary and xenograft
tumours were negative for CK5 and CK6 (data not shown) but
positive for CK14 expression as shown in Figure 1E and F. Both
tumour sample and HBCx-17 are negative for ERBB2 and oestrogen,
and progesteron receptor, and the clinical sample presented a strong
EGFR staining that the xenograft did not (data not shown).
To search for spontaneous lung metastasis of the HBCx-17
xenograft, mice lungs were analysed by histochemistry. Figure 1G
and H show two examples of small metastasis: clusters of tumour
Xenograft Primary
HES
Ki67
CK14
Figure 1 Representative haematoxylin-and-eosin-stained sections of patients and xenografts tumours. Haematoxylin and eosin sections Gx100 (A and
B), KI67 (C and D), and CK14 (E and F). Lung metastases are shown in pictures G and H (arrows) clusters of tumour cells obstruct the lumen of a small
number of pulmonary arterioles (cancerous emboli), without evident effraction of the arteriolar media.
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Figure 2 HBCx-17 tumour array CGH profiling of patient (top) and xenograft (bottom). Loss (green points), gain (red points), or amplification (blue
points) of chromosome material. Recurrence of copy number alterations (y axis) is plotted for each probe aligned along the x axis in chromosome order.
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scells obstructed the lumen of a small number of pulmonary
arterioles (cancerous emboli), without evident effraction of the
arteriolar media. Lung metastases were detected in 23% of mice
(six positive animals on 26).
CGH array and genomic alterations
The clinical sample and xenografted tumours at passages 0, 6, and
8 were characterised for genetic parameters using CGH array
technique (Figure 2). Comparative genomic hybridisation array
analysis showed a very high number of alterations and quite
similar gene copy number changes. The genomic profiles of the
primary tumour and different passages in the xenograft were very
similar, sharing large regions of DNA amplifications. Common
DNA gains and deletions are described in the Tables 1 and 2. These
amplifications are described in the Table 1 such as amplicons of
chromosome 1q and 8p.
Gene expression profiles
The histological classification of the HBCx-17 as a triple-negative
tumour was confirmed by quantitative RT–PCR analysis of the ER,
PR, and ERBB2 receptors (Table 3). Both the clinical sample and
the xenograft tumours were negative for the three receptors. By
contrast, the basal-like CK5 and CK6 were not expressed, but the
classification of basal-like breast cancer was done on CK14
expression as determined by IHC (Figure 1).
Table 1 Recurrent amplicons observed in the primary tumour and maintained in at least two passages of the xenograft
Cytogenetic
region
Start
position*
End
position* Candidate genes
Maximum xenograft
ratio (passage)
1q23.3–24.1 163.3 164.3 LMX1A, RXRG, LRRC52, MGST3, ALDH9A1, TMCO1, UCK2 2.1 (p8)
7q31.1 111.0 112.4 DOCK4, IFRD1, NPM1P14, TMEM168 2.2 (p0)
8p11.21 41.6 42.2 MIRN486, ANK1, MYST3, AP3M2, PLAT, IKBKB 2.12 (p8)
13q14.11–12 43.0 44.6 CCDC122, TSC22D1, NUFIP1 2.69 (p0)
18q11.2–12.1 19.6 24.3 CABYR, OSBPL1A, HRH4, RAC1P1, hCG1643695, SS18, PSMA8, TAF4B,
KCTD1, hCG38400, AQP4, CHST9, CDH2
3.3 (p0)
*UCSC Genome Browser on Human May Assembly; positions are given in megabased.
Table 2 Recurrent losses observed in the primary tumour and maintained through passages of the xenograft
Cytogenetic
region
Start
position*
End
position* Candidate genes
1p34.3 34.4 34.9 MIRN552
2q22.2 141.5 142.1 Not known
4p16.1–15.33 8.5 12.3 GPR78, CPZ, DUB4, DEFB131, DRD5, SLC2A9, MIST, MIRN572, HS3ST1
4p15.2 25.1 26.5 SLC34A2, RBPJ, CCKAR, TBC1D19, STIM2
4q35.1 186.8 189.0 SORB2, TLR3, CYP4V2, KLKB1, F11, MTNR1A, MRPS36P2
7p22.2–7p22.1 3.1 5.9 SDK1, FOXK1, RADIL, PAPOLB, MMD2, RBAK, WIPI2, SLC29A4, FBXL18, MIRN589, ACTB, EGID-654231
7p15.3 20.2 22.6 ITGB8, ABCB5, SP8, SP4, DNAH11, CDCA7L, RAPGEF5, MGC87042
7p15.1 28.3 29.9 CREB5, CPVL, CHN2, PRR15, WIPF3
30.1 31.1 MIRN550-1, NOD1, GARS, CRHR2, INMT, AQP1, GHRHR, ADCYAP1R1
7p14.3–14.1 32.5 43.0 MIRN550-2, KBTBD2, FKBP9, NT5C3, RP9, BBS9, BMPER, AAA1, NPSR1, TBX20, MERPUD2, hCG1642425, SEPT7, ANLN,
AOAH, ELM01, GPR141, TXNDC3, SFRP4, STARD3NL, T cell receptor gamma variable genes, AMPH, RALA, CDC2L5,
INHBA, GLI3, TCP1L1, PSMA2, MRPL32
7p12.3 46.0 47.1 EPS15L2
8p21.2 22.9 24.0 TNFRSF10C, TNFRSF10D, TNFRSF10A, CHMP7, R3HCC1, LOXL2, ENTPD4, SLC25A37, NKX3.1, NKX2.6, STC1
25.2 25.5 GNRH1, KCT9, CDCA2
25.7 26.3 EBF2, PPP2R2A, SDAD1P1
8p21.1 27.4 28.6 GULOP, CLU, SCARA3, CCDC25, PBK, PNOC, FBXO16, EXTL3
28.8 30.0 KIF13B, DUSP4, MAP2K1P1
31.9 32.1 NRG1
9p21.3 20.3 24.7 MIRN491, PTPLAD2, IFNB1, IFNW1, IFNxxxy, LEIF-M, MIRN31, MTAP, CDKN2A, CDKN2B, DMRTA1, ELAVL2
9p21.2–21.1 27.3 28.9 IFNK, LING02
10q22.1 72.1 74.2 SGPL1, PCBD1, SLC29A3, CDH23, PSAP, CHST3, SPOCK2, ASCC1, SSIT4, DNAJB12, CBARA1
10q23.31 89.7 91.4 LIPJ, LIPF, LIPK, LIPN, LIPM, ANKRD22, STAMBPL1, ACTA2, FAS, CH25H, IFIT2, LIPA
10q23.33–24.1 96.5 98.6 CYP2C19, CYP2C9, CYP2C8, PDLIM1, SORBS1, ALDH18A1, TCTN3, ENTPD1, CC2D2B, CCNJ, BLNK, DNTT, TMEM10,
TLL2, TM9SF3, PIK3AP1, MIRN606
11q25 131.7 133.7 OPCML, SPATA19, IGSF9B, JAM, PTP4AP2, NCAPD3, THYN1, ACAD8, GLB1L3
17p11.2 19.9 21.6 SPECC1, COTL1P2, MEIS3P2, RNASEH1P1, HSP22, DHRS7B, TMEM11, MAP2K3, KCNJ12
18q21.2–21.33 46.9 61.0 DCC, MBD2, POLI, STARD6, C18orf54, C18orf26, RAB27B, CCDC68, TCF4, AC009271.7, TXNL1, WDR7, AC100775.3,
ST8SIA3, ONECUT2, FECH, NARS, ATP8B1, AC022724.8, AC090324.7, NEDD4L, ALPK2, AC104971.5, MALT1,
AC104971.5, ZNF532, SEC11L3, GRP, RAX, CPLX4, LMAN1, CCBE1, PMAIP1, AC090377.15, MC4R, AC010928.7,
CDH20, RNF152, PIGN, KIAA1468, TNFRSF11A, ZCCHC2, PHLPP, AC015989.11, BCL2, FVT1, VPS4B, SERPINB5,
AC036176.8, SERPINB12, SERPINB13, SERPINB4, SERPINB3, SERPINB11, SERPINB7, SERPINB2, SERPINB10, SERPINB8
18q22.3 66.9 68.6 CBLN2
68.8 72.8 FBXO15, CYB5A, FAUP1, CNDP2, CNDP1
*UCSC Genome Browser on Human May Assembly; positions are given in megabased.
Table 3 Gene expression analysis of ERBB2, KI67, and ERa evaluated by
quantitative RT–PCR (overexpression limit of 1000 units)
ERBB2 Ki67 ERa
Patient tumour 8166 ( ) 6788 (++) 34 ( )
Xenograft tumour 10 533 ( ) 16 695 (+++) 6 ( )
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tumour as defined by the functional Fasay Assay (data not shown).
BRCA2 alterations
DNA sequencing of the primary tumour, and P0 and P8 from the
HBCx-17 xenograft showed the presence of the germline BRCA2
mutation identified in the patient (c.6033_6034delTT; p.Ser2012
GlnfsX5; Figure 3A). The informativity of the two studied markers
located at the BRCA2 locus, D13S260 and D13S1701, has allowed
detecting the presence of the two alleles at the germline DNA level,
whereas the primary tumour and the xenograft DNA showed loss
of one allele. Loss of heterozygosity (LOH) at the BRCA2 locus was
confirmed in the xenograft at P0 by using two flanking micro-
satellite markers for BRCA2, D13S260, and D13S1701 (Figure 3B).
To assess the LOH consequence on the BRCA2 protein, a protein
analysis was performed by western blot on cell lysate obtained from a
control breast tumour xenograft (having no BRCA2 mutation) and
from the HBCx-17 xenograft. As shown in Figure 3C, the BRCA2-
mutated xenograft lysate contains a truncated form of the BRCA2
protein and has lost the wild-type protein.
Quantitative multiplex PCR of short fluorescent fragments was
used to determine BRCA2 copy number. Figure 3D shows the
electrophoregrams of germline DNA, and P0 and P7 DNA (orange
and black). Mutated (BRCA2 duplicated) DNAs were used as
controls (green and red, respectively). Xenograft samples and
control samples were perfectly superimposed after normalisation,
indicating a duplication of BRCA2-mutated allele.
Tumour responses of xenograft to conventional
chemotherapies and radiotherapy
The HBCx-17 xenograft growth parameters (tumour latency and
tumour take) are published (Marangoni et al, 2007). Tumour
responses to standard chemotherapies used in the treatment of
breast cancer and radiotherapy have been studied. As shown in
Figure 4A, the HBCx-17 xenograft was a high responder to AC,
with five out of eight complete regressions and a TGI of 98%. The
HBCx-17 model was also sensitive to capecitabin-based treatment
with a TGI of 98% 4 weeks after start of the treatment. No response
was observed to docetaxel, as shown in Figure 4B. Cisplatin/
ifosfamide combination gave also an important growth inhibition
BRCA2
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Figure 3 (A) Chromatograms of tumour and normal breast tissue DNA showing BRCA2 mutation: (c.6033_6034delTT/p.Ser2012GlnfsX5) Germline
DNA (GDNA) shows both mutated and wild-type alleles. Loss of the wild-type allele with retention of the mutant one is shown in the primary tumour and
in passage 0 (P0) and 8 (P8) of the xenograft. (B): Amplification of two microsatellites (D13S260 and D13S1701) flanking BRCA2 shows loss of
heterozygosity in P0. (C) Illustrates an anti-BRCA2 immunoprecipitation on lysates generated from tumour sample HBCX-17 and 293T cells. Western blot
analysis detected full-length BRCA2 in the 293T samples and a truncated BRCA2 product of the predicted size in the tumour sample. (D) quantitative
multiplex PCR of short fragment shows that mutated allele is duplicated whereas wild-type allele is lost.
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Radiotherapy assays were done with a caesium irradiation source.
The mice received either 8 or 15Gy locally delivered in two
fractions of 7 and 8Gy. The xenograft was a high responder to
irradiation with a TGI of 73 and 75% at 8 and 15Gy, respectively
(Figure 4C).
DISCUSSION
In this work, we report the characterisation of a human breast
tumour xenograft obtained from a woman carrying a BRCA2
mutation. The basal-like morphology of the patient tumour was
conserved in the xenograft including the stroma component and
tissular architecture. Ki67 staining was higher in the xenograft’s
tumour than in the primary tumour, suggesting that tumour
engrafting may have selected highly proliferating cancer cells.
Studies on large series of BRCA2-associated breast cancers indicate
that these tumours are predominantly high-grade IDCs of no
special marker subtype, and that they are more often oestrogen-
and progesterone-receptor positive (Lakhani et al, 2002; Brekelmans
et al, 2007; Palacios et al, 2008). As the majority of BRCA2-
deficient cells, the tumour cells contain only the truncated BRCA2
protein, indicating that LOH has occurred as a consequence of an
inactivating mutation in the second allele. This is what normally
happens in most BRCA2-mutated tumour, where inactivation of
the wild-type allele occurs by LOH, abolishing normal protein
expression (Smith et al, 1992; Collins et al, 1995). In addition,
multiplex PCR of short fragment showed that loss of the wild-type
gene was associated with duplication of the mutated BRCA2
gene. LOH and copy number abnormalities are often associated
with BRCA1, and BRCA2-associated breast or ovarian cancer
(Staff et al, 2000).
Concordance between the clinical sample and xenograft was also
shown by CGH array analysis. Genetic profiles were very similar
not only between the patient tumour and the xenografts, but also
when comparing xenografts at different passages, suggesting that
although extremely altered, the HBCx-17 xenograft genetic profile
was stable during subsequent passages. The clinical sample and the
xenograft tumours present some of the chromosome alterations
that have already been frequently described in the genomic profiles
of BRCA2-mutated tumours, as gains of 8q and 20q, and loss of
13q (Palacios et al, 2008). The amplification of the MYST3 and
AP3M2 genes was already described like recurrent amplicons
associated with reduced survival duration in breast cancer
(Chin et al, 2006).
Gains in the regions 1q32–q41, 8q22.1–24.3, and 20q12–q13,
and loss in the region 8p23.3–p21.2 occur in both the primary and
xenograft tumours and have also been found in primary BRCA2
tumours by different authors (Gronwald et al, 2005; Jonsson et al,
2005).
However, none of these regions have been confirmed in large
number of patients and in studies of independent collections of
families, and more extensive studies are necessary to find
alterations specific to BRCA1/2-mutated tumours.
There is a significant body of preclinical data that supports the
hypothesis BRCA1/2-deficient cells are more sensitive to certain
chemotherapy agents than are the cells with intact BRCA1 and
BRCA2 proteins (Foulkes, 2006). In line with this, the HBCx-17
xenograft showed a pronounced sensitivity to anthracycline-based
chemotherapy with 450% of mice showing complete response
(no tumour recurrence), as well as to cisplatin and ifosfamide
combination. Although BRCA2 deficiency has not been extensively
studied, some previous works showed that decreased BRCA2
function is associated with increased in vitro sensitivity to
cisplatin, mitomycin, doxorubicin, and etoposide (Foulkes, 2006;
Robson, 2007a). The HBCx-17 xenograft was highly resistant to
docetaxel. Although some experiments raise the possibility that
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Figure 4 Tumour growth curves of HBCx-17 xenograft as a function of
time: HBCx-17 bearing mice were treated with two cycles of AC (A), a
combination of doxorubicin (2mgkg
 1 i.p. every three weeks) and
cyclophosphamide (100mgkg
 1 i.p. every three weeks), with docetaxel
(n) (20mgkg
 1 i.p. every three weeks) or capecitabin (B) (540mgkg
 1
per os 5 days per week two times) (B) or with a combination of cisplatin
(1mgkg
 1 i.p. once a week) and ifosfamide (90mgkg
 1, 3 consecutive
days every 3 weeks) (n) compared with 15Gy (E) or 7Gy (B)
irradiations (C). Controls (J) were not treated. Mice were treated at
day 1, and tumour volume was measured twice a week. Tumour growth
was evaluated by plotting the mean of the RTV±s.d. per group (each
group consisted of 10 mice) over time after first treatment.
Human BRCA2-mutated breast cancer xenograft
L de Plater et al
1198
British Journal of Cancer (2010) 103(8), 1192–1200 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sBRCA1-deficient cells may be resistant to anti-cancer agents
targeting the microtubules (such as vinca alkaloids and taxanes),
no preclinical in vivo studies have ever demonstrated taxane
resistance in BRCA2-deficient cells (Foulkes, 2006; Robson,
2007b). In the same way, some recent clinical analyses suggest
that primary resistance to docetaxel-based chemotherapy corre-
lates with BRCA1 mutations’ high frequency. No indications exist
for breast tumours occurring in BRCA2 mutation carrier. Our data
suggest that, like BRCA1, wild-type BRCA2 could be required for
in vivo response to mitotic spindle poisons and that the docetaxel
resistance could be attributed to BRCA1/2 involvement in the
taxane-induced stress response pathway.
In the clinic, the available evidence is not sufficient to conclude
that BRCA1/2-associated breast cancer is differentially sensitive to
specific conventional chemotherapeutic agents. In the adjuvant
setting, the choice of treatment regimen is not modified based on
the presence of such a predisposition. Clinical trials are in progress
to further address this issue. Nevertheless, the outcome of
hereditary breast cancer remains poor, addressing the questions
of potential new strategies that take advantage of the specific DNA
repair defects inherent in BRCA-deficient cells. The inhibition of
PARP1 potentiates the activity of DNA-damaging agents, such as
alkylating drugs, platinums, topoisomerase inhibitors, and radia-
tion in in vitro and in vivo models. Tumours with DNA repair
defects, such as those arising from patients with BRCA1/2
mutations, are more sensitive to PARP inhibition (Bryant et al,
2005; Farmer et al, 2005; Fong et al, 2009). In this context, the
HBCx-17 model could improve preclinical assays of PARP
inhibitors that are usually done in BRCA1/2 knockout mice or in
pancreatic cancer cells. Different agents are undergoing phase I
and II clinical trials in BRCA1/2-associated breast and ovarian
cancer, and new compounds are entering in the early preclinical
settings. In this perspective, the establishment of this new BRCA2
breast cancer xenograft reproducing, over successive generations,
the patient’s characteristics in terms of histology, genetic profile,
and biological characteristics may contribute to the preclinical
development of innovative therapeutics regimens.
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